Diversified Trust Co Purchases 4,454 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Diversified Trust Co increased its stake in Edwards Lifesciences Corporation by 14.9% during Q2, owning a total of 34,264 shares worth $2.68 million.
• Recent price target upgrades by multiple analysts see Edwards Lifesciences' stock rated between $80.00 and $95.00, reflecting a consensus rating of "Moderate Buy."
• Edwards Lifesciences reported earnings of $0.67 EPS for the last quarter, exceeding estimates, with revenue up 11.9% year-over-year at $1.53 billion.

Diversified Trust Co lifted its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 14.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 34,264 shares of the medical research company's stock after acquiring an additional 4,454 shares during the quarter. Diversified Trust Co's holdings in Edwards Lifesciences were worth $2,680,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC increased its position in shares of Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after acquiring an additional 145 shares during the last quarter. Pacific Capital Partners Ltd acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at about $1,760,000. Dynamic Advisor Solutions LLC increased its position in shares of Edwards Lifesciences by 2.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock valued at $1,124,000 after acquiring an additional 370 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after acquiring an additional 9,188 shares during the last quarter. Finally, Czech National Bank increased its position in shares of Edwards Lifesciences by 5.8% in the second quarter. Czech National Bank now owns 143,385 shares of the medical research company's stock valued at $11,214,000 after acquiring an additional 7,917 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EW. Evercore ISI lifted their target price on Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research report on Friday, July 25th. Barclays lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. The Goldman Sachs Group reiterated a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Piper Sandler lifted their price target on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $87.17.

Edwards Lifesciences Trading Down 0.2%

Shares of EW stock opened at $74.39 on Friday. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The stock has a market cap of $43.67 billion, a P/E ratio of 10.70, a price-to-earnings-growth ratio of 3.59 and a beta of 1.07. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a 50 day simple moving average of $78.69 and a 200 day simple moving average of $75.53.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the business earned $0.70 earnings per share. The company's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company's stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.